PSMA PET/CT分期对临床局限性前列腺癌长期结局的影响:大型单中心队列结果
该回顾性单中心队列纳入2013—2023年诊断的前列腺癌患者,最终分析6999例,其中505例(7.2%)在初诊分期时接受PSMA PET/CT。经倾向评分匹配和重叠加权等分析,PSMA PET/CT与更长的生化复发时间、癌症特异性生存和总生存相关,高危且接受放疗者获益尤其明显,但亚组差异仅为探索性。
要点
- PSMA PET/CT初诊分期与更长的BCR、CSS和OS相关,HR均小于1。
- 高危患者、尤其接受放疗者结局更好,但交互检验不显著,属探索性。
- 根治性前列腺切除术患者中未观察到统计学显著关联。
核心结论
- 大型真实世界队列支持PSMA PET/CT用于初诊分期的临床价值。
- 高危接受放疗者结果尤其有利,但亚组差异因交互检验不显著应视为探索性。
- 结果支持PSMA PET/CT可能改善患者选择、检出寡转移并提高治疗计划精度。
研究设计与样本
- 回顾性单中心研究,纳入2013—2023年诊断的全部11146例前列腺癌患者。
- 最终分析队列6999例,其中505例(7.2%)初诊分期接受PSMA PET/CT。
- 采用D'Amico风险分类将患者分为3组。
- 生存分析采用Kaplan-Meier法和校正Cox回归模型。
- 采用倾向评分匹配和重叠加权控制选择偏倚,并用界标分析处理选择偏倚和永恒时间偏倚,Fine-Gray模型在BCR分析中处理竞争死亡风险。
主要发现
- PSMA PET/CT与更长的BCR时间相关(HR=0.51;95%CI 0.38-0.68;P<0.001)。
- PSMA PET/CT与更长的CSS相关(HR=0.37;95%CI 0.22-0.61;P<0.001)。
- PSMA PET/CT与更长的OS相关(HR=0.54;95%CI 0.40-0.70;P<0.001)。
- 放疗组中OS的HR为0.42、BCR的HR为0.42、CSS的HR为0.25(均P<0.001),根治性前列腺切除术患者中未观察到统计学显著关联。
- 全部9项敏感性分析HR均持续低于1,提示获益方向一致。
关键数值与推荐
- PSMA PET/CT与BCR时间延长的HR=0.51(95%CI 0.38-0.68;P<0.001)。
- PSMA PET/CT与CSS延长的HR=0.37(95%CI 0.22-0.61;P<0.001)。
- PSMA PET/CT与OS延长的HR=0.54(95%CI 0.40-0.70;P<0.001)。
- 放疗组OS的HR=0.42、BCR的HR=0.42、CSS的HR=0.25(均P<0.001)。
- PSMA PET/CT与治疗方式间的正式交互检验未达统计学显著。
临床怎么用
- 初诊分期可考虑PSMA PET/CT以改善风险分层和患者选择。
- 高危且计划放疗者可能从PSMA PET/CT分期中获益更多,但需谨慎解读亚组结果。
- PSMA PET/CT可能有助于检出寡转移性疾病并提高治疗计划精度。
局限性
- 为回顾性单中心研究,仅505例(7.2%)接受PSMA PET/CT初诊分期。
- PSMA PET/CT与治疗方式交互检验不显著,亚组差异应视为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) PET/CT has become the gold standard for staging and restaging prostate cancer, with superior diagnostic accuracy over conventional imaging and established prognostic value. However, there are limited data on whether PSMA PET/CT-improved staging accuracy is associated with improved long-term patient outcomes. This study analyzes the association between PSMA PET/CT at primary staging and overall survival (OS), biochemical recurrence (BCR), and cancer-specific survival (CSS) in a large university hospital cohort at a center where PSMA PET/CT has been clinically available for over 13 y. Methods: This retrospective single-center study included all 11,146 patients with prostate cancer diagnosed between 2013 and 2023. The final analysis cohort consisted of 6999 patients, of whom 505 (7.2%) underwent PSMA PET/CT for primary staging. We classified patients into 3 groups using D'Amico risk classification. Survival analyses were performed using Kaplan-Meier methods and adjusted Cox regression models. To control for selection bias, propensity score matching and overlap weighting were applied. Landmark analysis addressed selection and immortal time biases, and Fine-Gray models accounted for competing risk of death in a BCR analysis. Results: PSMA PET/CT was associated with a longer time to BCR (hazard ratio [HR] = 0.51; 95% CI, 0.38-0.68; P < 0.001), longer CSS (HR = 0.37; 95% CI, 0.22-0.61; P < 0.001), and longer OS (HR = 0.54; 95% CI, 0.40-0.70; P < 0.001). PSMA PET imaging was associated with particularly better outcomes in high-risk patients, especially those treated with radiotherapy. In the radiotherapy group, the HRs were 0.42 for OS, 0.42 for BCR, and 0.25 for CSS (all P < 0.001), whereas no statistically significant association was observed in patients undergoing radical prostatectomy. As the formal interaction test between PSMA PET/CT and treatment modality was not statistically significant, this differential finding should be considered exploratory. Across all 9 sensitivity analyses, HRs were consistently below 1, indicating a uniform direction of benefit. Conclusion: The association observed in this large real-world cohort supports the clinical value of PSMA PET/CT for primary staging. Findings were particularly favorable among high-risk patients undergoing radiotherapy, although this subgroup difference should be interpreted as exploratory given the nonsignificant interaction test. These results support a potential role for PSMA PET/CT in improving patient selection and detecting oligometastatic disease, enabling higher precision in treatment planning.
引用
- Esmaeilzadeh Asl S, Hoberück S, Sonnenfeld A, et al. Impact of PSMA PET/CT Staging on Long-Term Outcomes in Patients with Clinically Localized Prostate Cancer: Results of a Large Single-Center Cohort. J Nucl Med. 2026. PMID: 42957210. doi:10.2967/jnumed.126.273261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。